Skip to main content
Menu
US

HTRF AAV1 Detection Kit, 10,000 Assay Points

The AAV1 Capsid kit is designed for the quantitative measurement of Adeno-associated virus serotype 1 (AAV1) particles in both cell lysates and cell supernatants.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Click to copy promo code to clipboard.
SAVE 15% NOW on online orders. Use promo code below.
YEAREND15
Offer valid until 12/15. Terms and conditions apply.
Feature Specification
Application Bioprocessing
Sample Volume 5 µL

The AAV1 Capsid kit is designed for the quantitative measurement of Adeno-associated virus serotype 1 (AAV1) particles in both cell lysates and cell supernatants.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Click to copy promo code to clipboard.
SAVE 15% NOW on online orders. Use promo code below.
YEAREND15
Offer valid until 12/15. Terms and conditions apply.
Product Variants
Unit Size: 500 Assay Points
Part #:
64AAV1PEG
List Price
USD 2,207.00
Unit Size: 10,000 Assay Points
Part #:
64AAV1PEH
List Price
USD 22,820.00

Overview

Adeno-associated virus (AA) vectors are the leading platform for gene delivery for the treatment of a variety of human diseases. AAV Serotype 1 (AAV1) is an efficient vector for gene delivery to skeletal muscle or the central nervous system. The AAV1 kit is designed to detect and quantify AAV1 particles in an easy-to-use, no-wash format. The simple and robust procedure benefits from increased throughput compared to ELISA.

Specifications

Application
Bioprocessing
Brand
HTRF
Detection Modality
HTRF
Lysis Buffer Compatibility
Lysis Buffer 1
Lysis Buffer 2
Lysis Buffer 3
Lysis Buffer 4
Product Group
Kit
Sample Volume
5 µL
Shipping Conditions
Shipped in Dry Ice
Target Class
Viral Particles
Technology
TR-FRET
Unit Size
10,000 Assay Points

Video gallery

How it works

AAV1 Capsid assay principle

The Adeno-Associated Virus serotype 1 (AAV1) assay measures AAV1 capsid in cell supernatant or cell lysate. The assay uses two anti-AAV1 antibodies: one coupled to HRP and which binds to anti-HRP d2 (acceptor) in premix 1, and the other coupled to biotin and which binds to Streptavidin Eu-cryptate (donor) in premix 2. In presence of AAV1 capsid in a cell extract or supernatant, the addition of these conjugates brings the donor fluorophore into close proximity with the acceptor, and thereby generates a FRET signal. Its intensity is directly proportional to the concentration of the capsid present in the sample, and provides a means of assessing any changes caused by experimental variability under a no-wash assay format.

1assay-principle-aav1-64aav1peg-64aav1peh-64aav1pey.svg

 

AAV1 Capsid assay protocol

The AAV1 Capsid assay protocol using a 384-well small volume white plate is described on the right. 5 µL of sample or standard and 5 µL of diluent are dispensed directly into the plate for detection by HTRF® reagents. The Biotin antibody anti-AAV1 is pre-mixed with Streptavidin labeled with the donor, and HRP anti-AAV1 was pre-mixed with anti-HRP labeled with the acceptor. 5 µL of each premix were added. The assay can be run in up to a 1536-well format by simply resizing each addition volume proportionally.

2assay-protocol-aav1-64aav1peg-64aav1peh-64aav1pey.svg

 

Assay details

standard curve Spike S1 kit
Sample size 5 µL
Final assay volume 20 µL
Time to result Overnight at RT
Detection limit (LOD) in diluent 2.76E+08 VP/mL
Dynamic range 9.73E+08 – 2.50E+11 VP/mL
Sample compatibility

From raw harvest material to the final product

Supernatant, Cell Lysate (LB#3)

 

3assay-specification-aav1-64aav1peg-64aav1peh-64aav1pey.svg

 

Analytical performance

Precision

Intra assay (n=24)

Sample Mean [AAV1] (VP/mL) CV
1 2.00E+11 4%
2 5.00E+10 5%
3 1.25E+10 4%
  Mean CV 4%

 

Each of the 3 samples was measured 24 times, and % CV was calculated for each sample.

Inter assay (n=4)

Sample Mean [AAV1] (VP/mL) CV
1 2.00E+11 2%
2 5.00E+10 4%
3 1.25E+10 8%
  Mean CV 4%

 

Each of the samples was measured in 3 independent experiments performed by different operators, and CV percentages were calculated for each sample.

 

Dilutional linearity

Dilution Factor

[AAV1] Expected

(VP/mL)

[AAV1] Mesured

(VP/mL)

Dilution Recovery

Neat

-

1.61E+11

100%

2

8.03E+10

7.38E+10

109%

4

4.01E+10

3.46E+10

116%

8

2.01E+10

1.73E+10

116%

16

1.00E+10

9.26E+09

108%

Mean

 

 

110%

 
Interferences

[AAV1]

(VP/mL)

[Total Protein]

SF9 cell lysates

Spiked Sample (mg/mL)

Recovery

1.0E+11

0.5

54%

0.375

59%

0.25

70%

0.125

81%

0.05

93%

 

[AAV1]

(VP/mL)

[Total Protein]

HEK293 cell lysates

Spiked Sample (mg/mL)

Recovery

1.0E+11

1.5

64%

0.75

96%

0.5

96%

0.375

94%

0.25

103%

 
Antigen Spike and Recovery

Sample

[AAV1] Standard

(VP/mL)

SF9 cell lysate (0.05 mg/ml)

   

Recovery

1

1.00E+11

93%

2

5.00E+10

96%

3

1.00E+10

101%

 

Mean CV

97%

 

 

 

Sample

[AAV1] Standard

(VP/mL)

HEK293 cell lysate (0.75 mg/ml)

Recovery

1

1.00E+11

96%

2

5.00E+10

98%

3

5.00E+09

93%

 

Mean CV

96%

Cross reactivities

Cross reactivities were assessed using other serotypes from the AAVs family. Standard curves were generated for each serotype using AAVs capsids diluted in the kit diluent. 5 µL of capsids were transferred into a white detection plate (384 low volume), and 5 µL of diluent followed by 10 µL of the HTRF AAV1 capsid detection reagents were added. The HTRF signal was recorded after an overnight incubation at room temperature. The assay showed differential affinities depending on the serotype, but did not detect AAV8 and AAV9.

 

4analytical-performance-aav1-64aav1peg-64aav1peh-64aav1pey-cross-reactivities.svg

 

Assay validation

Validation of HTRF AAV1 capsid detection on full and empty AAV1 particles

To demonstrate the detection of both full and empty AAV1 capsids, recognition of full AAV1-CMV-eGFP and empty AAV1 capsids were analyzed in the assay. A large range of AAV1-CMV-eGFP concentrations (GC/mL) were converted into VP/mL using an independent sample quantitation assay. 5 µL of full or empty capsids diluted in the kit diluent were then transferred into a white detection plate (384 low volume), and 5 µL of diluent followed by 10 µL of the HTRF AAV1 capsid detection reagents were added. The HTRF signal was recorded after an overnight incubation at room temperature. As expected, the HTRF AAV1 capsid detection assay could detect both full and empty AAV1 capsids in the same way.

5assay-validation-aav1-64aav1peg-64aav1peh-64aav1pey-full-empty-recognition.svg

 

Resources

Are you looking for resources, click on the resource type to explore further.

1-5 of 5 Resources
Whitepaper Icon
Whitepaper
Adeno-Associated Virus (AAV) Vectors Manufacturing

What Are the Challenges and Solutions?

All across the globe, AAVs are getting the attention of scientists and companies working in...

Whitepaper Icon
Whitepaper
Complete gene therapy review in a single industry report

With the increased understanding of molecular and cellular medicine, more specific and efficient gene transfer vectors are now...

Infographic Icon
Infographic
Gene therapy: what you need to know at a glance

When a genetic mutation occurs, it can lead to the development of different pathologies. Over the past 10 years exciting...

Guide Icon
Guide
HTRF solutions, guide to major applications

This guide provides you an overview of HTRF applications in several therapeutic areas.

Publication Icon
Literature - Publication Review
Using gene therapy to correct certain genetic disorders

See how researchers boost their gene therapy studies with Revvity technologies

The absence or mutation of protein is a factor that...

Scroll Icon